Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors
NCT07107230 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study is to determine recommended phase 2 doses (RP2Ds) of JNJ-95437446 in Part 1, and to further evaluate the safety of the RP2Ds in participants with advanced solid tumors in Part 2.
Conditions Studied
Interventions
- DRUG JNJ-95437446
Study Locations (8)
Other
- Severance Hospital Yonsei University Health System — Seoul
- Samsung Medical Center — Seoul
- Hosp Univ Vall D Hebron — Barcelona
- Hosp Univ Fund Jimenez Diaz — Madrid
- Hosp. Univ. 12 de Octubre — Madrid
- Hosp Univ Hm Sanchinarro — Madrid
Florida
- Florida Cancer Specialists — Sarasota
Virginia
- NEXT Oncology — Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 380 participants |
| Start Date | 2025-07-15 |
| Est. Completion | 2028-04-24 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07107230
The ClinicalTrials.gov registry entry for NCT07107230 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 380 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 442 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Colorectal Neoplasms appearing as the primary indexed condition, and to 1 intervention — of which JNJ-95437446 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT07107230 reports 8 study locations spanning 3 distinct geographic areas — top geographies include Other, Florida, Virginia. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT07107230 about?
NCT07107230 is a clinical study titled "A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors". The purpose of this study is to determine recommended phase 2 doses (RP2Ds) of JNJ-95437446 in Part 1, and to further evaluate the safety of the RP2Ds in participants with advanced solid tumors in Part 2.
What is the current status of trial NCT07107230?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 380 participants. The study started on 2025-07-15. Estimated completion is 2028-04-24.
What conditions does trial NCT07107230 study?
This clinical trial studies the following conditions: Colorectal Neoplasms. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT07107230?
The interventions under investigation include: JNJ-95437446 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT07107230?
This trial is sponsored by Janssen Research & Development, which has 442 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT07107230 being conducted?
This trial has 8 study locations across Florida, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.